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Abstract
Background: Biomarkers have been related to the arrhythmia recurrence following
catheter ablation (CA) of atrial fibrillation (AF). We hypothesized that concurrent
measurement of several biomarkers would additively improve their predictive value.
Methods: One thousand four hundred and ten consecutive AF patients (68% male;
57.2 ± 11.6 years) undergoing CA were enrolled. Baseline characteristics, serum B
type brain natriuretic peptide (BNP) and high sensitivity C reactive protein (hsCRP),
estimated glomerular filtration rate (eGFR), ablation parameters, arrhythmia data at
discharge, 1, 3, 6, and then every 6 months post CA were collected. Follow‐up
ended when arrhythmia recurred or until 31st December 2016.
Results: Three hundred and sixty‐five (25.9%) patients had arrhythmia recurrence
post‐CA during a mean follow‐up of 20.7 ± 8.8 months. BNP, hsCRP, and eGFR
levels and their cut‐off values of 237.45 pg/mL, 1.6 mg/dL, and 82.5 mL/min/
1.73 m2 were good predictors for AF recurrence (all P < 0.01). On multivariate anal-
ysis, increasing BNP and hsCRP, decreasing eGFR, gender, and early recurrence (ER)
were independent predictors of AF recurrence (all P < 0.01). Compared to BNP
alone, BNP plus eGFR or both eGFR and CRP showed incrementally better predic-
tive values (ROC comparisons, all P < 0.01). Similar findings were evident in the
subgroups of patients with paroxysmal or nonparoxysmal AF.
Conclusion: Measurement of BNP, CRP, and eGFR were incrementally additive to
clinical risk factors in a cumulative manner to improve prediction of arrhythmia
recurrence post‐CA of AF. The implications of poor arrhythmia outcome in AF
patients with multiple abnormal biomarkers pre‐CA procedure may help with patient
selection and inform the likelihood of success or the need of more complicated CA
procedure(s).
Yumei Xue and Gregory Y H Lip are joint senior authors.
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1 | INTRODUCTION
Catheter ablation (CA) of atrial fibrillation (AF) has been performed
for more than 20 years and is superior to antiarrhythmic drugs for
the prevention of AF recurrences.1 Relapses of AF post CA remain
common, and many factors have been associated with AF progres-
sion and recurrence.2 Based on clinical factors associated with
arrhythmia recurrence post‐CA, many clinical scoring systems have
been proposed.3 However, there is no general agreement of which
score or risk factor is best.
Biomarkers such as NT‐proBNP4,5 and CRP6 have been involved
in the development and recurrence of AF by inducing structural and
electrical remodeling.7 Chronic kidney disease (CKD) as defined by
the eGFR is also reported as a predictor of AF recurrence post‐CA.8
Previous reports on these biomarkers generally evaluated their
impact as a single predictor but no prior studies have investigated
their cumulative impact for predicting arrhythmia recurrent post‐CA
when used in a cumulative manner.
In this study, we tested the hypothesis that concurrent measure-
ment of several biomarkers reflecting different pathophysiological
processes would improve the predictive value of arrhythmia recur-
rence post‐CA.
2 | METHODS
This retrospective study enrolled 1410 consecutive symptomatic
adult patients with nonvalvular AF who underwent single CA proce-
dures from June 2011 to August 2015 in Guangdong General Hospi-
tal. Patients were refractory to at least one kind of anti‐arrhythmic
drugs (AADs). Baseline clinical data and ablation parameters were
extracted from hospital patient database. The study protocol was
approved by the Clinical Research Ethics Committee of Guangdong
General Hospital.
2.1 | Definitions
Paroxysmal AF (PAF) was defined as AF that spontaneously termi-
nated or with intervention within 7 days, persistent AF (PeAF) as AF
that lasted ≥7 days, and longstanding PeAF (LSPeAF) as AF lasted
>1 year.2 The term “nonparoxysmal” AF (NPAF) included PeAF and
LSPeAF. AF types in this study were divided into PAF and NPAF. All
patients had at least one symptomatic AF episode recorded before
the ablation procedure. Arrhythmia relapse was defined as any
symptomatic or asymptomatic atrial tachyarrhythmia (AF, atrial
tachycardia[AT] and/or atrial flutter[AFL]) lasting >30 seconds.
Arrhythmia relapse recorded within the 3‐month “blanking period”
after the ablation was defined as early recurrence (ER). Arrhythmia
relapse recorded 3 months post procedure without use of AADs was
defined as AF recurrence.
The estimated glomerular filtration rate (eGFR) was calculated
using the Modification of Diet in Renal Disease (MDRD) formula
(186 × Scr−1.154 × Age−0.203 × [1.210 if Black] × [0.742 if female]).9
A cut‐off value of each biomarker for predicting recurrence post‐CA
was tested using ROC analysis and was used to distinguish patients
with “normal” or “abnormal” biomarker serum level. “Abnormal bio-
marker levels” were defined as BNP and CRP levels higher than the
determined cut‐off value from ROC analysis, or eGFR levels below
the cut‐off value.
For the categorical analyses, we scored patients as having 0, 1,
2, and 3 points for those with none, 1, 2, or 3 abnormal biomarker
levels. Patients were divided into four groups according the different
points and the baseline clinical characteristics and AF relapses post‐
CA were compared.
2.2 | Laboratory tests
Peripheral blood samples were collected from each patient who
were fasting at the second morning after being hospitalized. All sam-
ples were sent to the central laboratory of the hospital within 1 hour
after collecting. Serum creatinine levels were determined by Jeffe
rate method (Synchron LX20, Beckman Coulter Inc, United State,
California; Sensitivity 8.84 μmol/L). Plasma BNP levels were deter-
mined by ELISA (EE/Cobas 601, Roche, Switzerland, Basel; NT‐pro‐
BNP, Detection range, 5‐35 000 pg/mL; Reference value <125 pg/
mL). Serum CRP was determined by Immunoturibidimetry (Immage
800, Beckman Coulter Inc, United State, California; Sensitivity
≤0.011 mg/dL; Reference value <0.744 mg/dL).
2.3 | Ablation procedure
Anticoagulation therapy, AAD therapy, and exclusion of thrombosis
procedure were performed following guideline recommendations.10
Radiofrequency ablation procedures were described detailed as
previously which in briefly following a stepwise protocol. The cry-
oballoon ablation procedure was consecutively performed as previ-
ously described.11 The endpoint of CPVI or cryoballoon catheter
ablation was bidirectional conduction block. A cavotricuspid isth-
mus (CTI) bidirectional block, super vena cava isolation (SVCI), lin-
ear ablation of LA roof or mitral isthmus, and complex
fractionated atrial electrograms (CFAE) were selected performed as
additional ablation. Pharmacological (ibutilide or aminodarone) or
electrical cardioversion (ECT) was performed during the procedure
when it was necessary.
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2.4 | Follow up
Follow up visits were performed at discharge, and at 1, 3, 6 months
and every 6 months thereafter. Data on symptoms, ECG and/or
24 hour ECG were collected in each visit. Patients complained to
symptoms related to arrhythmia recurrence within the visit interval
accepted additional ECG or 24‐hour Holter tests. Oral anticoagulants
and AAD (amiodarone or propafenone) were administrated to all
patients in the first 3 month post the ablation (blanking period).
Thereafter, oral anticoagulants were continued in patients with a
CHA2DS2‐VASc score of ≥2, while AAD use was at the discretion of
physicians.
Arrhythmia recurrence was defined as the principal study end-
point. Follow‐up period of patients with confirmed recurrence was
defined as the time of AF/AFL relapse. Patients without evidence of
recurrence were followed up for a minimum of 12 months.
TABLE 1 Characteristics and the difference between patients with AF recurrence or not
Characteristics Total (n = 1410)
Patients with
recurrence (n = 365)
Patients without
recurrence (n = 1045) P value*
Age (y) 57.18 ± 11.6 58.58 ± 11.3 56.69 ± 11.7 <0.01
Male 960 (68) 251 (68.8) 709 (67.8) 0.79
NPAF 321 (22.8) 162 (44.3) 159 (15.2) <0.01
AF history 2.70 ± 3.6 3.10 ± 3.8 2.56 ± 3.6 0.22
Cryoballoon 74 (5.2) 22 (6) 52 (5) 0.50
PVI 1394 (98.9) 362 (99.2) 1032 (98.8) 1.0
SCVI 87 (6.2) 19 (5.2) 68 (7.1) 0.45
CTI 337 (23.9) 120 (33) 217 (20.8) <0.01
CFAE 35 (2.5) 20 (5.5) 15 (1.4) <0.01
Linear 266 (18.9) 119 (32.6) 147 (14.1) <0.01
ST 247 (17.5) 71 (19.5) 176 (16.8) 0.27
Pharm CV 221 (15.7) 89 (24.4) 132 (12.6) <0.01
ECV 157 (11.1) 92 (25.2) 65 (6.2) <0.01
ER 317 (22.5) 196 (53.7) 121 (11.6) <0.01
FU (mo) 20.69 ± 8.8 10.05 ± 7.3 24.40 ± 5.6 <0.01
CHF 72 (5.1) 29 (7.9) 42 (4) <0.01
Hypertension 508 (36) 151 (41.2) 357 (34.2) 0.02
DM 143 (10.1) 40 (11) 103 (9.9) 0.55
Stroke/TIA 84 (6) 31 (8.5) 53 (5.1) 0.02
Vascular disease 49 (3.5) 13 (3.6) 36 (3.4) 0.75
AADs failed 0.97 ± 0.40 1.01 ± 0.42 0.96 ± 0.39 0.03
CAD 105 (7.4) 38 (10.4) 67 (6.4) 0.02
COPD 9 (0.6) 4 (1.1) 5 (0.5) 0.25
BBB 94 (6.7) 29 (7.9) 65 (6.2) 0.27
Smoking 244 (17.3) 62 (16.9) 182 (17.6) 0.87
Alcohol 75 (5.3) 20 (5.5) 55 (5.3) 0.89
LAD (mm) 36.9 ± 5.3 39.5 ± 5.9 36.0 ± 4.8 <0.01
EF 64.7 ± 6.1 63.0 ± 7.4 65.3 ± 5.5 <0.01
eGFR (mL/min/1.73 m2) 83.8 ± 6.1 73.3 ± 24.0 87.4 ± 25.6 <0.01
BNP (pg/mL) 319.5 ± 465.0 783.5 ± 637.3 158.4 ± 223.1 <0.01
hsCRP (mg/dL) 2.3 ± 3.7 4.5 ± 4.9 1.5 ± 2.9 <0.01
BMI (kg/m2) 25.5 ± 3.3 24.8 ± 3.6 24.4 ± 3.1 0.05
NPAF: AADs failed, refractory to anti‐arrhythmic drug; AF history, refers time that AF has been diagnosed; BBB, bundle branch block; BMI, body mass
index; BNP, B‐type natriuretic peptide; CAD, coronary artery disease; Cryoballoon, cryoballoon ablation; CRP, C reactive protein; CTI, cavo‐tricuspid
isthmus ablation; CFAE, complex fractionated atrial electrogram ablation; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; ECV,
electrical cardioversion; ER, early recurrence; EF, ejection fraction; FU, follow up period; eGFR, estimated glomerular filtration rate; HF, history of con-
gestive heart failure; LAD, left atrial diameter; Linear, linear ablation; Pharm CV, pharmaceutical cardioversion; PVI, pulmonary vein isolation; TIA, tran-
sient ischemic attack; SCVI, superior vena cava ablation; ST, with smart touch ablation catheter.
Chi‐square test and independent t test. *Statistically significant P < 0.05.
Variables are n (%) or mean ± SD.
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2.5 | Statistical analysis
All continuous variables were presented as mean ± standard devia-
tion and categorical variables were summarized as percentages.
The area under ROC curve (AUC) was used to test the predictive
probability of biomarkers or their combination for AF recurrence.
Cut‐off analyses were also performed with specificity and sensitiv-
ity calculated. ANOVA or Chi‐square tests were used to test the
differences in continuous or categorical variables among four
groups with none, 1, 2, or 3 abnormal biomarkers. The association
of the clinical variables with AF recurrence was analyzed using
univariate and multivariate Cox regression models. Cox propor-
tional‐hazards models with time‐dependent covariates for changing
biomarker combination and AF recurrence was built to evaluate
the independent effect of different biomarker combination on out-
comes.
Kaplan‐Meier analysis was used to test the difference of time‐
dependent outcome in patients between four groups patients with
different biomarker combination. Log rank tendency test was used
to compare the Kaplan‐Meier curve. A two‐sided P value of <0.05
was considered statistically significant. All the analyses were per-
formed using the SPSS software version 16.0 (IBM Corporation,
Armonk, NY, USA) and statistical software R version 3.0.2 (R Core
Team, 2013).
3 | RESULTS
We included 1410 patients (mean age 57.2 ± 11.6 years; 68%) male,
of which 1089 (77.2%) had PAF. Radiofrequency CA and cryoballoon
ablation were performed in 1336 and 74 patients respectively. Mean
follow‐up period was 20.7 ± 8.8 months. Recurrence occurred in
365 (27.9%) patients (18.6% PAF and 50.5% NPAF).
Clinical, biochemical, echocardiographic, and procedural charac-
teristics of patients with AF recurrence or not are summarized in
Table 1. Patients with AF recurrence were older and had larger left
atrial size, much more cardiac diseases or stroke, much more addi-
tional ablation, higher serum BNP and CRP, lower eGFR compared
to those without recurrence (all P < 0.05).
3.1 | Biomarkers and AF recurrence
Based on differences seen on the univariate comparisons in Table 1,
multivariate regression analysis using the variables that were
F IGURE 1 Receiver operating curve analysis of serum BNP, CRP, and eGRF. AUC, area under curve; ROC, receiver operating characteristic;
eGFR, estimate glomerular filtration rate; BNP, B type brain natriuretic peptide; CRP, C reactive protein
TABLE 2 Multivariate analysis of risk factors for AF recurrence
post ablation
Risk factors Hazard ratio (95% CI) P value*
Age 0.97 (0.96‐0.98) <0.01
NPAF 1.59 (1.26‐2.01) <0.01
ER 3.12 (2.48‐3.93) <0.01
CAD 1.46 (1.03‐2.07) <0.01
LAD (mm) 1.04 (1.02‐1.06) <0.01
eGFR (mL/min/1.73 m2) 0.96 (0.95‐0.97) <0.01
BNP (pg/mL) 1.00 (1.00‐1.001) <0.01
hsCRP (mg/dL) 1.06 (1.04‐1.08) <0.01
ER, early recurrence; CHF, history of congestive heart failure; LAD, left
atrial diameter; eGFR, estimated glomerular filtration rate; BMI, body
mass index); CI, confidence interval.
Multivariate Cox Regression analysis; *Statistically significant P < 0.05.
Adjusted for gender, alcohol consumption, smoking, presence of COPD,
heart failure, hypertension, diabetes mellitus, stroke/transient ischemic
attack, and body mass index.
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significant found only that age, AF types, prior history of coronary
artery disease (CAD), LAD, early recurrence (ER), BNP, and CRP
emerged as independent risk factors of AF recurrence, as was low
eGFR (see Table 2).
Using ROC analysis for biomarkers as continuous variables, good
predictive ability for AF recurrence was evident for eGFR (AUC
0.74, CI 0.71‐0.77, P < 0.001), CRP (AUC 0.82, CI 0.79‐0.85,
P < 0.001) and BNP (AUC 0.90, CI 0.88‐0.92, P < 0.001) (Figure 1).
Cut‐off analyses gave eGFR, CRP, and BNP values of 82.5 mL/min/
1.73 m2 (specificity 64%, sensitivity 74%), 1.6 mg/dL (specificity
76%, sensitivity 79%), and 237.45 pg/mL (specificity 79%, sensitivity
87%), respectively, as biomarker levels that were predictive of AF
recurrence.
Using these cut‐off values to categorize normal or abnormal val-
ues, covariate regression analysis gave hazard ratios for eGFR (HR
2.07, CI 1.63‐2.65, P = 0.001), CRP (HR 3.04, CI 2.32‐3.99,
P = 0.001), and BNP (HR 7.0, CI 5.05‐9.72, P = 0.001) as indepen-
dent predictors for AF recurrence (see Table 3). ROC analysis
demonstrated good predictive ability of the categorized “cut‐off val-
ues” of eGFR, CRP, and BNP, with AUCs of 0.69 (CI 0.66‐0.72), 0.78
(CI 0.75‐0.81), and 0.83 (CI 0.81‐0.86) respectively (all P < 0.001;
Figure 2).
3.2 | Predictive value for AF recurrence by
combining multiple biomarkers
As the biomarker with the largest AUC, the cut‐off of BNP was
then combined with other biomarkers. The AUCs of BNP alone,
BNP plus eGFR, then BNP plus eGFR, and CRP were 0.83 (CI
0.81‐0.86), 0.85 (CI 0.83‐0.88), and 0.90 (CI 0.88‐0.92), respec-
tively, with differences that were significant (P < 0.001, Delong's
method) (see Figure 3).
We scored patients as having 0, 1, 2, and 3 points for those with
none, 1, 2, or 3 abnormal biomarker levels. With increasing points,
patients had corresponding increases in AF recurrence events (trend
P < 0.001), ER events (trend P < 0.001) and left atrial size (trend
P < 0.001) (see Table 4). History of various cardiovascular comor-
bidities (trend, P < 0.001) also increased with increasing points.
Increasing points were associated with more pharmacological or
electricial cardioversion, as well as linear or complex fractionated
atrial electrograms (CFAE) ablation (all P < 0.001; see Table 4).
TABLE 3 Cut‐off value of biomarkers and their predictive value
for AF recurrence under multivariate analysis
Risk factors
Hazard ratio
(95% CI) P value*
Gender 0.80 (0.64‐1.00) 0.046
ER 2.80 (2.25‐3.49) <0.01
eGFR ≤ 82.5 mL/min/1.73 m2 2.07 (1.63‐2.65) <0.01
BNP ≥ 237.45 pg/mL 7.00 (5.05‐9.72) <0.01
hsCRP ≥ 1.6 mg/dL 3.04 (2.32‐3.99) <0.01
ER, early recurrence; eGFR, estimated glomerular filtration rate; BNP, B
type brain natriuretic peptide; CRP, C reactive protein); CI, confidence
interval.
Multivariate Cox Regression analysis; *Statistically significant P < 0.05.
Adjusted for age, nonparoxysmal AF, alcohol consumption, smoking,
presence of COPD, coronary artery disease, heart failure, hypertension,
diabetes mellitus, stroke/transient ischemic attack and body mass index.
F IGURE 2 Area under curve of BNP, CRP, and eGFR (using cut‐
off value). AUC, area under curve; ROC, receiver operating
characteristic; eGFR, estimate glomerular filtration rate; BNP, B type
brain natriuretic peptide; CRP, C reactive protein
F IGURE 3 Area under curve of combining biomarkers and
comparison. AUC, area under curve; ROC, receiver operating
characteristic; eGFR, estimate glomerular filtration rate; BNP, B type
brain natriuretic peptide; CRP, C reactive protein. BNPeGFR = BNP
plus eGFR; BNPeGFRCRP = BNP plus eGFR plus CRP
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When adjusted by gender, age, history of prior stroke/TIA, heart
failure, coronary artery disease, hypertension, diabetes mellitus, non-
paroxysmal AF, early recurrence, left atrial diameter, and body mass
index, multivariate Cox regression analysis showed that patients with
two or three abnormal biomarkers had rapid increasing risk of AF
recurrence (all P < 0.01) when compared to those without abnormal
biomarkers (see Table 5). Using multivariate analysis, patients with-
out abnormal biomarkers had a lower risk of AF recurrence
(P < 0.01) with no statistically significant association in those with
only one abnormal biomarker (P > 0.05). Apart from two or multiple
abnormal biomarkers, those patients at younger age, with large left
atrial diameter and early recurrence were independent predictors of
AF recurrence on multivariate analysis (P < 0.05). Nonparoxysmal AF
was not an independent predictor using multivariate analysis
(P > 0.05).
Kaplan‐Meier analysis demonstrated that the sinus rhythm main-
tenance rate decreased sharply with increasing “abnormal biomarker”
points while the risk of AF recurrence increased (see Figure 4). Similar
findings were evident in the subgroups of patients with paroxysmal
or nonparoxysmal AF, where increasing “abnormal biomarker” points
were related to more AF recurrence (see Figures 5, 6).
4 | DISCUSSION
In this study, of the impact on arrhythmia outcome by using three
biomarkers our main findings are as follows: (a) eGFR, CRP, and BNP
were independent predictors of AF relapse post CA; and (b)
Biomarkers had accumulative predictive effect when used in combi-
nation. Thus, measurement of multiple biomarkers, including BNP,
TABLE 4 Characteristics of patients with or without accumulated numbers (given as points) of abnormal biomarkers
Characteristics Total Group 1 (0 point)a Group 2 (1 point)a Group 3 (2 points)a Group 4 (3 points)a P value*
n (%) 1410 (100) 431 (30.5) 469 (33.3) 276 (19.6) 234 (16.6)
Recurrence 364 (25.8) 9 (2.1) 34 (7.2) 123 (44.6) 199 (85)b <0.01
Age (y) 57.3 ± 11.5 53.9 ± 12.4 58.1 ± 11.1 57.6 ± 11.6 61.1 ± 9.8 <0.01
LAD (mm) 36.9 ± 5.3 34.9 ± 4.7 36.5 ± 4.8 38 ± 5.5 39.8 ± 5.6b <0.01
BMI (kg/m2) 24.5 ± 3.3 24.2 ± 3.3 24.7 ± 3.0 24.4 ± 3.1 24.9 ± 3.7 <0.01
EF (%) 64.7 ± 6.1 65.1 ± 6.2 64.6 ± 6.0 63.3 ± 6.5 63.9 ± 6.5 0.031
Fu (mo) 20.7 ± 8.8 23.9 ± 6.2 23.4 ± 7.0 18.1 ± 9.3 12.4 ± 9.1 <0.01
Male 960 (68.1) 300 (69.6) 322 (68.7) 189 (68.5) 149 (63.7) 0.45
NPAF 320 (22.7) 53 (12.3) 80 (17.1) 83 (30.1) 105 (44.9)b <0.01
COPD 9 (0.6) 0 4 (0.9) 2 (0.7) 3 (1.2) 0.20
HF 71 (5) 7 (1.6) 14 (3) 24 (8.7) 26 (11.1)b <0.01
Hyperternsion 508 (36.1) 113 (26.2) 179 (38.2) 105 (38) 111 (47.4) <0.01
DM 143 (10.1) 30 (7) 67 (14.3) 25 (9.1) 21 (9) <0.01
Stroke/TIA 84 (6) 19 (4.4) 21 (4.5) 16 (5.8) 28 (12) <0.01
CAD 105 (7.4) 17 (3.9) 32 (6.8) 29 (10.5) 27 (11.5)b <0.01
Cryoballoon 74 (5.2) 18 (4.2) 31 (6.6) 8 (2.9) 17 (7.3) 0.05
ECV 157 (11.1) 25 (5.8) 33 (7.0) 39 (14.1) 60 (25.6)b <0.01
ER 317 (22.5) 49 (11.4) 69 (14.7) 81 (29.3) 123 (52.6)b <0.01
PVI 1391 (98.7) 426 (98.8) 464 (98.9) 271 (98.2) 233 (99.6) 0.28
Linear 266 (18.9) 54 (12.5) 60 (12.8) 70 (25.4) 82 (35)b <0.01
CFAE 35 (2.5) 4 (0.9) 7 (1.5) 11 (4) 13 (5.6)b <0.01
CTI 337 (23.9) 90 (20.9) 91 (19.4) 76 (27.5) 80 (34.2)b <0.01
SCVI 87 (6.2) 28 (6.5) 31 (6.6) 14 (5.1) 14 (6.0) 0.85
Pharm CV 221 (15.7) 45 (10.4) 59 (12.6) 56 (20.3) 61 (26.1)b <0.01
BMI, body mass index; BNP, B‐type natriuretic peptide; CAD, coronary artery disease; Cryoballoon, cryoballoon ablation; CRP, C reactive protein; CTI,
cavo‐tricuspid isthmus ablation; CFAE, complex fractionated atrial electrogram ablation; COPD, chronic obstructive pulmonary disease; DM, diabetes
mellitus; ECV, electrical cardioversion; ER, early recurrence; EF, ejection fraction; FU, follow up period; eGFR, estimated glomerular filtration rate; HF,
history of congestive heart failure; LAD, left atrial diameter; Linear, linear ablation; NPAF, non‐paroxysmal atrial fibrillation; Pharm CV, pharmaceutical
cardioversion; PVI, pulmonary vein isolation; Re, recurrence; TIA, transient ischemic attack; SCVI, superior vena cava ablation.
Variables are n (%) or mean ± SD; Chi‐square test and ANOVA test; *Statistically significant P < 0.05.
aGroup 1, no abnormal biomarkers (0 point); Group 2, one abnormal biomarker (1 point); Group 3, two abnormal biomarkers (2 points); Group 4, three
abnormal biomarkers (3 points). Abnormal biomarker cut‐offs, as defined in Table 3.
bCompared to other three groups.
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CRP, and eGFR were incrementally additive to clinical risk factors in
a cumulative manner to improve prediction of arrhythmia recurrence
post‐CA of AF. Similar findings were evident in the subgroups of
patients with paroxysmal or nonparoxysmal AF, where increasing
“abnormal biomarker” points were related to more AF recurrence.
4.1 | Biomarkers and catheter ablation outcome
Biomarkers especially inflammatory indices have been related to the
AF relapse post CA. Many inflammatory factors, including CRP,12,13
TNF‐α, ET‐1,14 CD 36,7 and heat shock protein,15 as well as other
F IGURE 4 Kaplan‐Meier curves of freedom from atrial
tachyarrhythmias. Biomarker abnormal, serum BNP/CRP ≥ the cut‐
off value or eGFR ≤ the cut‐off value; 0, Patients without biomarker
abnormal; 1, Patients with any one biomarker abnormal; 2, Patients
with any two biomarkers abnormal; 3, Patients with three
biomarkers abnormal
TABLE 5 Multivariate analysis of combining biomarkers for AF
recurrence
Categories Adjusted HR (95% CI) P value*
Group 1a 0.29 (0.14‐0.60) 0.01
Group 3 6.70 (4.57‐9.82) <0.01
Group 4 14.09 (9.63‐20.63) <0.01
Age 0.99 (0.98‐1.00) 0.046
LAD 1.02 (1.00‐1.04) 0.018
ER 2.90 (2.33‐3.61) <0.01
HR, hazard ratio; Biomarkers (BNP, B type brain natriuretic peptide; CRP,
C reactive protein; GFR, glomerular filtration rate); CI, confidence inter-
val.
Multivariate Cox regression analysis; *Statistical significant, P < 0.05.
aReference group; Group 1, no abnormal biomarkers (0 point); Group 2,
one abnormal biomarker (1 point); Group 3, two abnormal biomarkers (2
points); Group 4, three abnormal biomarkers (3 points). Abnormal biomar-
ker cut‐offs, as defined in Table 3.
Adjusted for gender, body mass index, COPD, smoking, alcohol consump-
tion, presence of coronary artery disease, heart failure, hypertension, dia-
betes mellitus, stroke, transient ischemic attack, and nonparoxysmal AF.
F IGURE 5 Kaplan‐Meier curves of different sums of abnormal
biomarkers in the PAF subgroup. (Footnote as Figure 4)
F IGURE 6 Kaplan‐Meier curves of different sums of abnormal
biomarkers in the NPAF subgroup. (Footnote as Figure 4)
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biomarkers of cardiac hemodynamic stress such as BNP16 and oxida-
tive stress markers17 had been associated with AF recurrence.18,19 A
previous meta‐analysis has shown that CRP was associated with
higher risk of AF recurrence in patients underwent catheter
ablation.20
BNP is elevated in AF patients with increased atrial pressure,4
and has been related to AF recurrence post CA.19,21 Serum BNP was
found to be elevated preablation and declined postablation in patients
with persistent AF, and BNP was reported as independent predictor
of AF recurrence in the study.22 Similarly, CKD as diagnosed by
decreased eGFR has been related to AF recurrence post CA.8,23 In
our analysis, we found that serum BNP and CRP significantly elevated
and eGFR decreased in patients with AF recurrence. Meanwhile,
using multivariate analysis with a Cox hazard model, high cut‐off val-
ues of BNP (≥237.45 pg/mL), CRP (≥1.6 mg/dL), and eGFR
(≤82.5 mL/min/1.73 m2) were all independent predictors for AF recur-
rence of our cohort. Although all three biomarkers were individual
predictors, the present study also shows how these biomarkers are
additive in combination, for predicting AF recurrence post‐CA.
To evaluate the additive predictive ability in combination of
BNP, CRP, and eGFR, we also scored patients when they had one or
more “abnormal” biomarkers. Patients with different points pre-
sented numbers of “abnormal” biomarkers and the association of the
points and the AF recurrence illustrates the additive predictive ability
of biomarkers in combination. The cut‐off value of biomarker was
used to divide serum level as “normal” or “abnormal” in our study
population, and we recognize that a local laboratory “abnormal cut‐
off value” could be different based on different cohorts. For exam-
ple, in our cohort, BNP ≥ 237.45 pg/mL was defined as “abnormal”,
while in another study cohort, “abnormal” BNP was defined as ≥
423.20 pg/mL.4
4.2 | Cumulative predictive impact of combing
biomarkers
Several clinical scores are combination of several risk factors used to
predict arrhythmia outcome of patients with AF post CA.3 Many
clinical risk factors were included in these scores but only the ALAR-
MEc24 and APPLE9 score, which included eGFR as one of the risk
factors. Indeed, Shaikh et al included BNP ≥ 100 pg/mL as an addi-
tional biomarker predictor added to the CHADS2, CHA2DS2‐VASc,
R2CHADS2 and HATCH scores and reported significantly improved
the predictive probability of these clinical scores for arrhythmia
recurrence post CA in patients with AF.25
In this study, patients undergoing CA had increasing risk of AF
recurrence when quantity of abnormal biomarkers was increased.
Patients with more abnormal biomarkers required more additional
ablation or cardioversion during the procedure which perhaps implies
the presence of a more complicated AF substrate.
Our findings show that baseline biomarkers levels measured
before an ablation procedure have good predictive value for AF
recurrence postablation. Most clinical scores derived for predicting
AF recurrence include important risk factor(s) for early recurrence,
allows predict only following the ablation procedure; nevertheless,
baseline biomarkers levels may be used as an alternative tool for
estimation of the likelihood of AF recurrence, and help with
patients selection.
4.3 | Limitations
This was a single centre, retrospective, and observational study.
While patient follow‐up was based on symptoms, 12 lead ECG
and 24 hour Holter ECG examinations during follow‐up visits,
asymptomatic AF might still be missed. The follow‐up period was
limited, and patients undergoing multiple ablation procedures were
not included. About 1% patients of this cohort had accepted
ablation elsewhere before the enrolment which might also have
implications for ablation outcomes, but our objective was to study
a complete “real world” cohort of patients undergoing CA our
centre—not to focus on selected subgroups which may be small
and underpowered. We do recognize that recurrent risk factors of
PAF and NPAF may be different as well as the impact of each
biomarker(s) in combination in these separate subgroups.
Nevertheless, we are clearly underpowered for detailed analyses
of the PAF and NPAF subgroups separately, and our subgroup
analyses in relation to recurrences with increasing “abnormal bio-
marker” points (Figures 5 and 6) should only be regarded as
exploratory.
In conclusion, multiple biomarkers, including BNP, CRP, and
eGFR are incrementally additive to clinical risk factors in a
cumulative manner to improve prediction of arrhythmia recur-
rence post‐CA of AF. The implications of poor arrhythmia out-
come in AF patients with multiple abnormal biomarkers pre‐CA
procedure may help with patient selection and inform the likeli-
hood of success or the need of more complicated CA procedure
(s).
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